STOCK TITAN
  1. Home
  2. News
  3. ASXC

Asensus Surgical, Inc. - ASXC STOCK NEWS

Welcome to our dedicated page for Asensus Surgical news (Ticker: ASXC), a resource for investors and traders seeking the latest updates and insights on Asensus Surgical stock.

Asensus Surgical, Inc. (NYSE American: ASXC) is a trailblazing medical device company that enhances minimally invasive surgery through digital laparoscopy. The company's flagship product, the Senhance® Surgical System, is the first machine vision system used in robotic surgery. It leverages augmented intelligence, connectivity, and robotics to address clinical, cognitive, and economic challenges in surgery.

Headquartered in Research Triangle Park, North Carolina, Asensus Surgical focuses exclusively on the research, development, and sale of medical device robotics aimed at improving surgical outcomes. The company's cutting-edge technology includes the Intelligent Surgical Unit™ that brings augmented intelligence into the operating room. One of its latest innovations is the LUNA™ Surgical System, a next-generation robotic and instrument system under development.

Committed to global healthcare improvements, Asensus Surgical has expanded its reach with the Senhance System now available in the US, EU, Japan, Russia, and select other countries. The system has recently been adopted by Nagoya University Hospital in Japan, dedicated to pediatric procedures. This marks a significant milestone, as the Senhance System offers specialized instrumentation and advanced clinical intelligence, aimed at reducing invasiveness and increasing precision in pediatric surgery.

In a recent strategic move, Asensus Surgical entered into a definitive merger agreement with KARL STORZ Endoscopy-America, Inc., a subsidiary of KARL STORZ SE & Co. KG. This merger, valued at $0.35 per share, is anticipated to enhance KARL STORZ's portfolio and market presence, particularly in the robotic surgical market. The transaction has been unanimously approved by Asensus’ Board of Directors and is expected to close during the third quarter of 2024.

Asensus Surgical continues to be driven by collaboration and human ingenuity, striving to make surgery more accessible and predictable while delivering consistently superior outcomes. For more detailed information, visit www.asensus.com.

News

Asensus Surgical, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Asensus Surgical, Inc. (ASXC) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News

Asensus Announces Sale of Senhance Robotic System in Romania

Rhea-AI Summary
Asensus Surgical, Inc. (NYSE American: ASXC) announced the sale of a Senhance® Surgical System to be placed in Louis Turcanu Clinical Emergency Hospital for Children in Timisoara, Romania. The system, designed for pediatric procedures, aims to enhance outcomes and patient well-being. The hospital's Department of Pediatrics is eager to explore new possibilities and continually improve surgical technology for the betterment of patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.9%
Tags
none
-
News

Senhance Robotic System Sold by Asensus Surgical

Rhea-AI Summary
Asensus Surgical, Inc. (NYSE American: ASXC) announced the sale of a Senhance® Surgical System to be placed in a hospital in the Commonwealth of Independent States region, marking the second system sold to the region in the past month. Anthony Fernando, President and CEO, expressed excitement about partnering with another institution to deliver better patient outcomes through their advanced digital laparoscopic platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
none
News

Asensus Surgical, Inc. Reports Operating and Financial Results for the Third Quarter 2023

Rhea-AI Summary
Asensus Surgical, Inc. (NYSE American: ASXC) announced its operating and financial results for the third quarter 2023. Key highlights include 17% growth in surgical procedures, two Senhance Surgical programs initiated in the quarter, and $33.1 million cash and cash equivalents at September 30, 2023. The company also provided updates on the LUNA Surgical System, market development, and 2023 milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
earnings
-
News

Asensus Surgical Announces Sale of Senhance Robotic System

Rhea-AI Summary
Asensus Surgical, Inc. (ASXC) announced the sale of a Senhance® Surgical System to be placed in a pediatric hospital in the Commonwealth of Independent States (CIS) region. The system's specialized technology aims to reduce invasiveness and enhance precision in pediatric patients, offering potential improvements in patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
-
News

Asensus Surgical, Inc. Announces Agreement with Flex for Design and Advanced Manufacturing Services for the LUNA™ Surgical System

Rhea-AI Summary
Asensus Surgical, Inc. (NYSE American: ASXC) announces an agreement with Flex (NASDAQ: FLEX) for design and advanced manufacturing services for the LUNA Surgical System, a next-generation surgical robot platform. Flex will provide services to enable Asensus Surgical to deliver the platform at scale, faster, including design for manufacturing services and a trusted supply chain network. Asensus Surgical President and CEO, Anthony Fernando, emphasizes the potential of LUNA to revolutionize surgery, while Flex's President, Randy Clark, highlights the impact of surgical robotics technology on patient care globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
News

Asensus Surgical, Inc. Schedules Third Quarter Financial and Operating Results Conference Call for November 14, 2023

Rhea-AI Summary
Asensus Surgical, Inc. (NYSE American: ASXC) will release its 2023 third quarter financial and operating results on November 14, 2023, after the market closes. A conference call to discuss the results will take place at 4:30 p.m. ET on the same day, with a webcast available. Access details for the call and webcast are provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News

Asensus Surgical Announces Klinikum Idar-Oberstein Hospital in Germany to Initiate Senhance Surgery Program

Rhea-AI Summary
Asensus Surgical, Inc. announced that Klinikum Idar-Oberstein Hospital in Germany has entered into a lease agreement to utilize a Senhance Surgical System. The collaboration aims to enhance patient outcomes through advanced minimally invasive surgery. The Senhance System, with its innovative features and established laparoscopic approach, is expected to bring valuable enhancements to the hospital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
none
-
News

Asensus Surgical Announces Collaboration with NVIDIA to Enhance Augmented Intelligence Capabilities of the ISU

Rhea-AI Summary
Asensus Surgical collaborates with NVIDIA to enhance the development of its Intelligent Surgical Unit (ISU) and improve clinical intelligence capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.14%
Tags
none
News

Asensus Surgical to Participate in the H.C. Wainwright 25th Annual Global Investment Conference and 2023 Cantor Global Healthcare Conference

Rhea-AI Summary
Asensus Surgical, Inc. to participate in investment conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What is the current stock price of Asensus Surgical (ASXC)?

The current stock price of Asensus Surgical (ASXC) is $0.3395 as of August 22, 2024.

What is the market cap of Asensus Surgical (ASXC)?

The market cap of Asensus Surgical (ASXC) is approximately 94.9M.

What does Asensus Surgical, Inc. do?

Asensus Surgical, Inc. digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. Its flagship product is the Senhance® Surgical System.

Where is Asensus Surgical headquartered?

Asensus Surgical is headquartered in Research Triangle Park, North Carolina, USA.

What is the Senhance® Surgical System?

The Senhance® Surgical System is the first machine vision system used in robotic surgery, enabling augmented intelligence, connectivity, and robotics to improve surgical outcomes.

What is the latest innovation from Asensus Surgical?

Asensus Surgical is developing the LUNA™ Surgical System, a next-generation robotic and instrument system as part of its digital surgery solution.

In which regions is the Senhance® Surgical System available?

The Senhance® Surgical System is available in the US, EU, Japan, Russia, and select other countries.

Has Asensus Surgical recently partnered with any hospitals?

Yes, Asensus Surgical recently partnered with Nagoya University Hospital in Japan to use the Senhance® Surgical System for pediatric procedures.

What is the merger agreement with KARL STORZ about?

Asensus Surgical entered into a definitive merger agreement with KARL STORZ Endoscopy-America, Inc. to enhance KARL STORZ's portfolio in the robotic surgical market.

When is the merger with KARL STORZ expected to close?

The merger with KARL STORZ is expected to close during the third quarter of 2024.

Will Asensus Surgical continue to be publicly traded after the merger?

No, upon completion of the merger, Asensus Surgical will become a subsidiary of KARL STORZ and will no longer be publicly listed or traded on the NYSE American Exchange.

How can I learn more about Asensus Surgical's products?

You can learn more about Asensus Surgical's products by visiting their official website at www.asensus.com.

Stock ASXC logo
Asensus Surgical, Inc.

NYSE:ASXC

ASXC Rankings

#4437 Ranked by Market Cap
N/A Ranked by Dividends

ASXC Stock Data

94.92M
267.22M
2.06%
18.27%
4.14%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
DURHAM